| Data | Hora | Fonte | Título | Código | Companhia |
| 03/05/2019 | 17:36 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 26/04/2019 | 17:53 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 24/04/2019 | 12:58 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 23/04/2019 | 17:19 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 23/04/2019 | 17:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 23/04/2019 | 10:28 | GlobeNewswire Inc. | Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, ... | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 23/04/2019 | 10:01 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 18/04/2019 | 03:00 | GlobeNewswire Inc. | Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, In... | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 17/04/2019 | 16:25 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 20/03/2019 | 18:06 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquistion (definitive) (defm14a) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 15/03/2019 | 17:42 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 15/03/2019 | 08:00 | GlobeNewswire Inc. | OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 07/03/2019 | 18:41 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 07/03/2019 | 18:00 | GlobeNewswire Inc. | OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 14/02/2019 | 20:23 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 14/02/2019 | 09:59 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 05/12/2018 | 11:10 | GlobeNewswire Inc. | Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 09/11/2018 | 11:00 | GlobeNewswire Inc. | OncoMed Announces Early Clinical Data for anti-TIGIT Antibody | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 01/11/2018 | 17:26 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 01/11/2018 | 17:05 | GlobeNewswire Inc. | OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 22/10/2018 | 09:00 | GlobeNewswire Inc. | OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian... | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 17/10/2018 | 20:01 | Dow Jones News | OncoMed Says Celgene Won't Exercise Option to License Rosmantuzumab | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 09/10/2018 | 09:00 | GlobeNewswire Inc. | OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology M... | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 24/09/2018 | 17:00 | GlobeNewswire Inc. | OncoMed to Present at the Cantor Global Healthcare Conference | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 24/09/2018 | 09:00 | GlobeNewswire Inc. | OncoMed Announces Publication of Phase 1a Data of Navicixizumab | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 20/09/2018 | 09:59 | Dow Jones News | OncoMed Says Celgene Won't Exercise Option to License Navicixizumab | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 20/09/2018 | 09:00 | GlobeNewswire Inc. | OncoMed Provides Update on Navicixizumab Partnership | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 29/08/2018 | 17:00 | GlobeNewswire Inc. | OncoMed to Present at Two Upcoming Investor Conferences in September | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 21/08/2018 | 17:57 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |
| 02/08/2018 | 09:00 | GlobeNewswire Inc. | OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights | NASDAQ:OMED | Oncomed Pharmaceuticals, Inc. |